Yingli Pharma Enrolls First Patient in Phase I Study for KRAS Inhibitor YL-17231 at MD Anderson
Yingli Pharma, a US-based biopharmaceutical company focused on developing therapies for both the Chinese and...
Yingli Pharma
Yingli Pharma’s Linperlislib Receives Priority Review Status for Lymphoma Treatments
US-based Yingli Pharma, a company dedicated to developing drugs for both the Chinese and US...
Yingli Pharma’s YL-17231 Receives NMPA Approval for Clinical Trials in Advanced Solid Tumors
US-based Yingli Pharma, a company dedicated to developing drugs for both the China and US...
NMPA Conditionally Approves Yingli Pharma’s Linperlisib for Lymphoma
The National Medical Products Administration (NMPA) website indicates that linperlisib, a Category 1 anti-tumor drug,...
Yingli Pharma Doses First Patient in Linperlisib Phase II Trial for PTCL
US-based Yingli Pharma, which targets the China and US drug markets, has dosed the first...